Document:

Exhibit 10.1

                                    AGREEMENT
          BETWEEN THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW
                   YORK AND MEDISCIENCE TECHNOLOGY CORPORATION

      This  Agreement  is  made  and  entered  into as of  June  10  ,2002  (the
"Effective Date"), between The Research Foundation of The City University of New
York, a New York non-profit corporation having its central office at 555 W. 57th
St. New York, NY 10019 U.SA ("FOUNDATION") and Medisience Technology Corporation
having  its  principal  office at 1235  Folkstone  Way,  Cherry  Hill,  NJ 08034
MEDISCENCE").

                                   WITNESSETH

WHEREAS,  FOUNDATION  owns  certain  technology  and  wishes  to  enter  into an
agreement for the commercialization of this technology with Mediscience, and;

WHEREAS, FOUNDATION and MEDISCIENCE previously entered into a Research Agreement
("Research  Agreement")  for  the  development  and  commercialization  of  said
technology  dated June 1, 1992 and amended said agreement from time to time, the
last amendment being August of 2001 and;

WHEREAS.  FOUNDATION and MEDISCIENCE again wish to amend terms and conditions of
Research Agreement,

Now therefore, the parties agree to the following terms and conditions.

                                    ARTICLE 1
                                  DEFINITIONS

      For the purposes of this Agreement,  the following words and phrases shall
havethe following meanings;

1.1   FIELD  OF USE  shall  mean  all  medical  applications  of the  foundation
                                  --------------------------
      technology   embodied  in  patent   applications   and/or  the  foundation
      technology  defined and detailed in "Attachment A"  exclusively,  provided
      that  said  technology  was not in the  public  domain  at the time ft was
      disclosed to MEDISCIENCE.

1.2   LICENSED  PRODUCT  shall  mean  any  product,   which  embodies,   or  the
      manufacture,  use or sale of which  employs,  any of the  RFCUNY  patents/
      patent applications in "Attachment A" exclusively.

1.3   NET SALES shall mean MEDISCIENCE'S gross revenues from the sale or license
      of products to independent third parties less either;

      A- Discounts allowed in amounts customary in the trade for direct sales

<PAGE>

      B- Sales taxes,  tariff duties and/or use taxes directly  imposed and with
         reference to particular sales
      C- Outbound transportation prepaid or allowed
      D- Amounts  allowed  or  credited  on  returns  or 10% of  gross  revenues
         whichever is greater
      E- Licensed products shall be deemed to have been sold when paid for
      F- For the purpose of calculating net sales the invoice cost of the entire
         system shall be ulillzed to the extent the system  incorporates  any of
         the technology represented in Attachment A

      1.4   "Patent  Application" shall mean ail Patent  Applications and issued
             -------------------
            Patents listed in "Attachment A", (see 1.1 and 1.2}

      1-5   " Royalties"  shall  mean  royalties  paid or payable by MEDISCIENCE
              ---------
            to FOUNDATION as described in Article 4,

      1.6   "Territory" shall mean world-wide
             ---------

                                    ARTICLE 2
                                     GRANT

      2.1   The FOUNDATION  agrees to extend  MEDISCIENCE'S  right to exclusive,
            transferable   worldwide,   irrevocable   licenses   in   foundation
            technology  listed in  "Attachment  A". Terms and conditions of said
            licenses  are set  forth  in the  agreement  entered  into in  1992,
            attached  hereto.  Paragraph  5.G is amended to allow  MEDISCIENCE a
            period of five (5) years  from The  Effective  Date of this  Amended
            agreement  to  offer  for  sale  Licensed  Products,  embodying  the
            technology  referred  to in  Attachment  A and subject to Article 4,
            herein.

      2.2   FOUNDATION  retains  the  right  to use  the  Technology  listed  in
            "Attachment  A"  for  research,  teaching  and  other  educationally
            related purposes.

      2.3   MEDISCIENCE may grant sublicenses  consistent with the terms of this
            Amended Agreement and the 1992 Agreement MEDISCIENCE must deliver to
            FOUNDATION  a true and correct  copy of each  sublicense  granted by
            MEDISClENCE,  and any  modification or termination  thereof,  within
            thirty (30) days of  execution,  modification,  or  termination,  if
            -this Agreement is terminated,  all existing  sublicenses granted by
            MEDISCIENCE must be assigned to FOUNDATION

                                  BEST EFFORTS

      3.1   MEDISCIENCE  represents to  FOUNDATION  that it will continue to use
            its best efforts to commercialize the Technology through the sale of
            licensed  Products  in the  Territory.  MEDISCIENCE  will report its
            efforts to the FOUNDATION once a year.

      3.2   In the event that MEDISCIENCE  fails to commercialize the Technology
            in  "Attachment  A" within five (5) years from the Effective Date as
            this Amended Agreement,  FOUNDATION will have the right to terminate
            this  Agreement  and all  FOUNDATION  rights  to the  Technology  in
            "Attachment A" will revert to the FOUNDATION.

<PAGE>

                                    ARTICLE 4

                 PAYMENTS, ROYALTIES & PATENT COST REIMBURSEMENT

      4.1   in  consideration  of  the  rights  granted  under  this  Agreement,
            MEDISCIENCE  will pay  Royalties to  FOUNDATION  in the manner shown
            below:

            (a)   A  royalty  equal  to 3 1/4 % of the  Net  Sates  of  Licensed
                  Product; without differentiation as to which patents represent
                  what percentage of the final product.

            (b)   A royalty equal to 40% of any payments received by MEDISCIENCE
                  from a sub-licensee  in connection  with sates and/or licenses
                  of licensed Product; and

            (c)   SINGLE  Annual  License fee for all  foundation  patent/patent
                  applications  of  "Attachment  A" according  to the  following
                  schedule:

                  i.    $5,000 on the second anniversary of Ms Agreement, or one
                        year  after  the   receipt  of   funding   for   product
                        development and commercialization, whichever is sooner;

                  ii    $ 10,000 on the th W and  fourth  anniversaries  of this
                        Agreement; and

                  iii.  $20,000  on the fifth and  subsequent  anniversaries  of
                        this agreement,  unless  royalties due under (a) and (b)
                        above  exceed  $20,000 in which  case there  shall be no
                        license fee.

      4.2   MEDISCIENCE  shad pay to  FOUNDATION  the  royalties due and payable
            under this Agreement quarterly,  no later than sixty (60) days after
            December 31st and June 30* of each year. If no royalties are due, it
            shall be so reported.

      4.3   Amounts payable hereunder by MEDISCIENCE shall be payable irt United
            States funds without  deductions  for taxes,  assessments,  fees, or
            charges of any kind.

      4.4   MEDISCIENCE  's  obligation  to pay  royalties to  FOUNDATION  shall
            continue for each LICENSED PRODUCT, until the expiration of the test
            to expire valid claim of a patent relating to such LICENSED PRODUCT.

      4.5   MEDISCIENCE shall pay all costs and maintenance fees associated with
            all  patent   applications  and  issued  patents  both  foreign  and
            domestic.  MEDISCIENCE  shall  reimburse  FOUNDATION for any and all
            reasonable  expenses  incurred by FOUNDATION in connection  with the
            Patent  Applications  and Patents costs or fees that are incurred in
            the event of default of payment by MEDISCIENCE.

<PAGE>

                                    ARTICLE 5
                                OUTSTANDING DEBT

      5.1   MEDISCIENCE agrees to the following financial terms and conditions;

A)  MEDISCIENCE  will issue  MEDISCIENCE  Common Shares on the basis of $.25 per
share as payment of 25% ($70,807.00) of the outstanding debt owed to FOUNDATION.
Two Hundred and Eighty Three  Thousand  Two Hundred and Twenty  Eight  (283,228)
shares will be issued in the name of the Research  Foundation of City University
of New York.

B) MEDISCIENCE  will make a cash payment of $85,045.00  representing  30% of the
outstanding amount of $283,483.00 owed to the Research Foundation.  Payment will
be made by MEDISC1ENCE  upon execution of this  agreement.  Failure to make this
payment will render this agreement null and void.

C)  MEDISCIENCE  will grant a 5-year option to FOUNDATION or nominee to purchase
600,000  shares  of  MEDISCIENCE  Common  at $1.00  per  share in  exchange  for
cancellation  of the  remaining  45% of debt The  parties  agree that at anytime
during this five year period MEDISCIENCE retains the right to tender the balance
due  FOUNDATION  in cash as full  payment  canceling  and voiding  this  option,
FOUNDATION  may  exercise  this  option at anytime  within the five year  period
beginning  on the  Effective  Date  of  this  Amended  Agreement  If  FOUNDATION
exercises its option,  MEDISCIENCE 's right to tender the balance due is limited
to the amount of the option unexercised by FOUNDATION.

D) The financial  obligations  established  herein represent the full and entire
understanding of the parties for all patents, patent applications,  licenses and
payments owed by virtue of any prior agreement or amendment thereto.

                              ARTICLE 6 REPORTS AND
                                     RECORDS

      6.1   MEDISCIENCE,  on March 1 and September 1 of each year, shall deliver
            to FOUNDATION a true and accurate  report of the business  conducted
            by MEDISCIENCE and any sub-licensee  MEDISCIENCE executes during the
            preceding  six (6) month  period  under this  Agreement  Such report
            shall include at least the following:

            (a)   Total  number of unite of Licensed  Product  sold or licensed,
                  and price per unit;
            (b)   Discounts  as  defined  in  the  definition  of Net  Sales  in
                  paragraph 1,3; and
            (c)   Total Royalties and payments due,

      6.2   Simultaneously  with the  delivery of the report  described  in 6.1,
            MEDISCIENCE  shall pay to FOUNDATION the Royalties,  if any, due for
            the period covered by such report. If no Royalties are due, it shall
            be so reported.

      6.3   MEDISCIENCE  shall keep  full,  true and  accurate  books of account
            containing all  particulars,  which may be necessary for the purpose
            of computing and  verifying the amount  payable to FOUNDATION by way
            of Royalty as  aforesaid.  Said books of  accounts  shall be kept at
            MEDISCIENCE'S  principal place of business or the principal place of
            business  of a  division  of  MEDISCIENCE  which  is  marketing  the
            Licensed Products.  Said books and the supporting data shall be open
            at all reasonable times, for five (5) years following the end of the
            calendar  year  to  which  they  pertain,   to  the   inspection  of
            FOUNDATION'S  Internal  Audit  Division  and/or  of  an  independent
            certified  public   accountant   retained  by  FOUNDATION  and/or  a
            certified public accountant employed by FOUNDATION,  for the purpose
            of verifying  MEDISCIENCE's  report required in 6.1 or compliance in
            other respects with this license.  executes during the preceding six
            ($) month period under this  Agreement  Such report shall include at
            least the following:

<PAGE>

            (d)   Total  number of unite of Licensed  Product  sold or licensed,
                  and price per unit;
            (e)   Discounts  a$  defined  in  the  definition  of Net  Sales  in
                  paragraph 1,3; and
            (f)   Total Royalties and payments due,

      6.4   Past due royalty amounts owed to Foundation by Mediscience  pursuant
            to this  Section 6 shall bear  interest at the rate of 1% per month.
            If any audit  pursuant  to section 6.3  reveals an  underpayment  to
            Foundation  of greater  than ten  percent 10% of the amount due then
            MEDISCIENCE  shall further pay the reasonable and documented cost of
            such audit

                                    ARTICLE 7
                                    PATENTS

      7.1   MEDISCIENCE   shall,   with  counsel  selected  by  MEDISCIENCE  and
            reasonably acceptable to FOUNDATION, prepare, apply for, seek prompt
            issuance  of, and  maintain  during the term of this  Agreement  the
            patents/patent  applications  listed in  Attachment  A in the United
            States The  preparation,  and to provide comments to FOUNDATION with
            respect to the  preparation,  filing and  prosecution of tie patents
            which  comments  shall be given due  consideration  by FOUNDATION in
            connection  with the foregoing,  MEDISC1ENCE  shall keep  FOUNDATION
            fully informed as to the Status of patent matters  described in this
            Article,  including without limitation,  by providing FOUNDATION the
            opportunity, as far in advance of filing dates as possible, to fully
            review extensions.  comment on any documents which will be tilted in
            any  patent  office,   and  providing   FOUNDATION   copies  of  any
            substantive  documents  that  MEDISCIENCE  receives from such patent
            offices   promptly   after   receipt,   including   notice   of  all
            interferences, reissues, re-examination, oppositions or requests for
            patent term prosecution, filing, fifing jurisdiction and maintenance
            of the  Patents/patent  applications  in "Attachment A" shall be the
            primary responsibility of MED1SC1ENCE.

      7.2   MEDISCIENCE, with Foundation's assistance will secure and maintain a
            copy  file of ail the  Patents  and  Patents  Pending  reflected  in
            "Attachment A" from the patent attorney of record  including but not
            limited to documents of preparation,  prosecution,  filing,  and all
            amendments  and ail other  necessary  patent  maintenance  documents
            whatsoever  filed  with the Patent  office.  Such copy file shall be
            available  to  FOUNDATION  in  the  ordinary   course  of  business.
            MEDISCIENCE  shall  supplement such file with necessary  material as
            requested.

                                    ARTICLE 8

                       UNLICENSED ACTIVITY AND NFRINGEMENT

      8.1   FOUNDATION  and  MEDISCIENCE  shall  promptly  inform  the  other in
            writing of any  infringement of the patents/  patent  application or
            other proprietary  technology by a third party and provide available
            legal evidence of infringement

      8.2   If  within   thirty   (30)  days  after   notification   of  alleged
            infringement  MEDISCIENCE  has not been successful in persuading the
            alleged  infringer to desist and is not   diligently  prosecuting an
            infringement  action or if  MEDISCIENCE  notifies  FOUNDATION of its
            intent not to bring action against the alleged infringer. FOUNDATION
            may,  but is not  obligated  to, bring action at its own expense and
            may us(C) the name of MEDISCIENCE as party plaintiff.

      8.3   In any suit  involving  the  enforcement  or  defense  of the rights
            relating to the  technology  or the patents,  the other party hereto
            agrees,  at the  request and  expense of the party  initiating  such
            suit, to cooperate in all respects and to have its employees  and/or
            its  patent  attorney  with all  necessary  records,  patent  office
            memorandum and law office work product testify when requested and to
            make  available  relevant  records,  papers,  information,  samples,
            specimens and the like,

<PAGE>

      8.4   No  settlement  or  consent   Judgment  or  other   voluntary  final
            disposition  of an  enforcement  and/or  defense  suit  initiated by
            either  party to the  Agreement-may  be  entered  into  without  the
            consent  of  the  other,  which  consent  WHS  not  be  unreasonably
            withheld.

      8.5   In the event a declaratory  judgment action  alleging  invalidity or
            non-infringement  of the  technology  or patents is brought  against
            MEDISCIENCE,  MEDISCIENCE Shall have the right to defend itself with
            counsel of its choosing, but FOUNDATION reserves the right to retain
            its own counsel,  at its own expense,  to work with  MEDISCIENCE and
            FOUNDATION'S  counsel  in the  joint  defense  of such  action,  and
            MEDISCIENCE shall cooperate with FOUNDATION and FOUNDATION'S counsel
            in such  effort.  FOUNDATION  shall  not be  liable  for any  losses
            incurred  as  the  result  of  an  jetton  alleging   invalidity  or
            infringement  brought against MEDISCIENCE as the result of any right
            granted under this Agreement.

      8.6   The cost of any infringement  action commenced or defended solely by
            FOUNDATION   shall   be   borne   by   FOUNDATION.   Recoveries   or
            reimbursements  from such action shall first be applied to reimburse
            FOUNDATION  for its actual costs  incurred in  connection  with such
            action.  Any remaining  recoveries  shall be allocated in accordance
            with  4.1  (a) and (b)  with  the  exception  that  punitive  damage
            recovery  shall be allocated  between  MEDISCIENCE  and  FOUNDATION,
            equally.

      8.7   The  cost  of any  infringement  action  commenced  or  defended  by
            MEDISCIENCE shall be borne by MEDISCIENCE. MEDISCIENCE, however, may
            withhold  royalties  in any given  calendar  year and apply the same
            towards reimbursement of its expenses and any recovery of damages by
            MEDISCIENCE   from  any  such  suit  shall  be   applied   first  in
            satisfaction  of  any  un-reimbursed  expenses  and  legal  fees  of
            MEDISCIENCE  relating  to the suit or  settlement  thereof,  and the
            balance of such recovery  shall be allocated in accordance  with 4.1
            (a) and (b) with the exception that punitive  damage  recovery shall
            be allocated between Foundation and MEDISCIENCE, equally.

                                    ARTICLES
                                CONFIDENTIALITY

      9.1   MEDISCIENCE  hereby  acknowledges  and  agrees  that the  Technology
            "Attachment  A"  constitutes  and  contains   valuable   proprietary
            information of FOUNDATION,  embodying  substantial  creative efforts
            and confidential information,  ideas, and expressions.  Accordingly,
            MEDISCIENCE agrees to treat (and take precautions to ensure that its
            employees  treat) the Technology as  confidential in the same manner
            it protects the  confidentiality of similar  information and data of
            its own (at all times  exercising  at least a  reasonable  degree of
            care in the protection of confidential information),

            FOUNDATION  hereby  acknowledges  and  agrees  that  the  FOUNDATION
            Technology  (see 1.4 (G) and (H)  above)  constitutes  and  contains
            valuable proprietary information of FOUNDATION embodying substantial
            creative  efforts  and   confidential   information,   ideas,   grid
            expressions.  Accordingly,  FOUNDATION  agrees  to treat  (and  take
            precautions  to ensure (hat its employees  treat) the  Technology as
            confidential in the same manner it protects the  confidentiality  of
            similar  information and data of its own (at all times exercising at
            least a reasonable  degree of care in the protection Of confidential
            information

<PAGE>

      9.2   FOUNDATION  acknowledges  that the  unauthorized  use,  transfer  or
            disclosure of the technology or copies thereof will

            (i)   substantially   diminish  the  value  to  MEDISCIENCE  of  the
                  proprietary interests that are the subject of this Agreement;
            (ii)  renders remedy at law for such unauthorized use, disclosure or
                  transfer inadequate; and
            (iii) cause  irreparable  injury  in a  short  period  of  time,  if
                  MEDISCIENCE  breaches any of its  obligations  with respect to
                  the use or confidentiality of the , _ Technology,  MEDISCIENCE
                  shall be entitled to equitable relief to protect its interests
                  therein,  including,  but  not  limited  to,  preliminary  and
                  permanent injunctive relief.

            MEDlSCiENCE  acknowledges  that the  un-authorized  use, transfer or
            disclosure of the  FOUNDATION  Technology or copies thereof (see 4.1
            (G) and (H) above) will
                    (I)     substantially diminish the value to FOUNDATION of
                            the proprietary interests that are the subject of
                            this Agreement;
                    (ii)    render FOUNDATION'S remedy at law for such
                            unauthorized use, disclosure or transfer inadequate;
                            and
                    (iii)   cause irreparable injury in a short period of time.
                            If FOUNDATION breaches any of its obligations with
                            respect to the use or confidentiality of the
                            Technology, FOUNDATION shall be entitled to
                            equitable relief to protect its interests therein,
                            including, but not limited to, preliminary and
                            permanent injunctive relief.

      9.3   FOUNDATION'S and MEDISCIENCE's obligations under this Article 9 will
            survive the  termination of this Agreement or of any license granted
            under this Agreement for whatever reason.

                                   ARTICLE 10
                                GOVERNMENT RIGHTS

      10.1  MEDISCIENCE  understands  that  part,  some  or all  the  technology
            reflected in "Attachment A" may have been developed  under a funding
            agreement  with the  Government of the United States of America and,
            if so,  that  the  Government  may  have  certain  rights  relatives
            thereto.   This   Agreement  Is  explicitly   made  subject  to  the
            Government's  rights under any such agreement and any applicable law
            or  regulation,  if any.  To the  extent  that  there Is a  conflict
            between any such  agreement,  applicable  law or regulation and this
            Agreement,  the terms of such Government agreement applicable law or
            regulation  shall  prevail.  Distribution  of the  Technology to any
            government agency by MEDISCIENCE shall not be subject to the Royalty
            set forth herein.

<PAGE>

                                   ARTICLE 11
                  NO LICENSOR WARRANTY; LIMITATION OF LIABILITY

      11.1  IT IS SPECIFICALLY  UNDERSTOOD AND AGREED THAT THE TOTAL  TECHNOLOGY
            IN  Attachment  A"  IS  FURNISHED  BY  FOUNDATION  "AS  IS"  WITHOUT
            REPRESENTATION  OR WARRANTY AS TO ACCURACY,  APPLICABILITY,  FREEDOM
            FROM   INFRINGEMENT  OF  ANY  PATENT  RIGHTS,   COPYRIGHT  OR  OTHER
            PROPRIETARY  RIGHTS,  OR THE  RIGHTS OF THIRD  PARTIES  OR ANY OTHER
            WARRANTY OR  REPRESENTATION.  FOUNDATION HEREBY EXPRESSLY WAIVES ALL
            WARRANTIES,   EXPRESS,  IMPLIED  OR  STATUTORY,  INCLUDING,  WITHOUT
            LIMITATION,  ANY IMPLIED WARRANTIES OF  MERCHANTABILITY,  FITNESS OR
            FREEDOM FROM INFRINGEMENT WITH RESPECT TO THE TECHNOLOGY.

            IN  NO  EVENT   WHATSOEVER   SHALL  FOUNDATION  BE  LIABLE  FOR  ANY
            CONSEQUENTIAL OR SPECIAL DAMAGES OR CLAIMS FOR LOST PROFITS.

                                   ARTICLE 12
                  FOUNDATION WARRANTY AND INDEMNITY; INSURANCE

      12.1  MEDISCIENCE shall be solely responsible for all warranties,  express
            or  implied,   with  respect  to  the  Licensed  Products  utilizing
            "Attachment  A"  technology,  and shall  indemnify and hold harmless
            FOUNDATION,  The City University of New York, City College, and each
            of their trustees,  directors,  officers,  agents and employees from
            and against  any dams,  demands,  or causes of action  caused by, or
            arising out of, or resulting  from,  the exercise or practice of the
            license granted hereunder to MEDISCIENCE by FOUNDATION,  MEDISCIENCE
            's  sub-licensees,  if any,  its  subsidiaries  or  their  officers,
            employees,  agents or representatives,  including without limitation
            any  claims,  demands,  or causes of action  arising  on  account of
            MEDISCIENCE's  modification  or enhancement of the  Technology,  and
            shall assurme and pay all damages,  liabilities, or costs {including
            reasonable attorneys' fees) resulting from, based upon or arising in
            connection  therewith,  unless  it can be  shown  that  such  claims
            resulted fnorn the lack of full disclosure by, and/or  negligence on
            the part of the  FOUNDATION,  The City  University of New York,  its
            officers, directors, agents or employees.

      12.2  Without limitation on FOUNDATION'S  obligations as aforesaid,  prior
            to the initiation of marketing activity by MEDISCIENCE  MEDISCIENCE,
            at its own cost and expense,  shall maintain  comprehensive products
            liability  insurance  with an insurer of  recognized  responsibility
            protecting FOUNDATION against any and all claims and liabilities for
            injury or damage to  persons or  property  or for loss of life or of
            property  caused by or resulting  from the Licensed  Products with a
            policy limit of no less than one million  dollars (U.S.  $1,000,000)
            per occurrence and shall provide  FOUNDATION  promptly with evidence
            thereof prior to initiation of such activity. MEDISCIENCE shall have
            FOUNDATION, The City University of New York, protected as additional
            named insured under such policy and shall  provide  FOUNDATION  with
            copy of such policy.

<PAGE>

                                   ARTICLE 13
                                   ASSIGNMENT

      13.1  MEDISCIENCE may not assign or otherwise  transfer this Agreement and
            the rights granted herein relative to Foundation  patents and patent
            applications  reflected in  "Attachment A" without the prior written
            consent of the  FOUNDATION,  such  consent  not to be  un-reasonably
            withheld

      13.2  MEDISCIENCE may assign or otherwise  transfer this Agreement and the
            license  granted hereby and the rights  acquired by it hereunder per
            "Attachment  A* so  long  as  such  a  sale  or  other  transfer  is
            accompanied by

            a.    a sale or other transfer of MEDISClENCE's ENTIRE BUSINESS or

            b.    Sate or other transfer of that part of MEDISClENCE's  business
                  to which the  license of  "Attachment  A".  patents and patent
                  applications granted hereby relates.

            c.    MEDISClENCE'  may assign or otherwise  transfer this Agreement
                  and the license  granted hereby and the rights  acquired by it
                  hereunder if such assignment or transfer is accompanied by the
                  transfer of the rights to  manufacture,  use, make, have made,
                  offer for sate, and/or market the "Attachment A" technology as
                  a LICENSED PRODUCT, and such assignee or transferee has agreed
                  in  writing  to be bound by the terms and  provisions  of this
                  Agreement,  in which event,  MEDISClENCE' shall be released of
                  liability hereunder..

            d.    MEDISCIENCE  shall  give  FOUNDATION  sixty  (60)  days  prior
                  written notice of such proposed assignment and transfer.  Upon
                  such  assignment  or transfer of Agreement by such assignee or
                  transferee,  the term MEDISCIENCE as used herein shall include
                  such assignee or transferee.

                                   ARTICLE 14
                              TERM AND TERMINATION

      14.1  The term of this Agreement  shall commence on the Effective Date and
            continue   until  the   expiration  of  the  last  to  issue  patent
            "Attachment A" and any allowable extensions under the law, whichever
            is longer,  unless earlier  terminated in accordance  with paragraph
            14.2 below.

      14.2  Either  party  hereto  shall  have  the  right  to  terminate   this
            Agreement,  immediately  by written notice to the other party in any
            of the following events:

            (a)   If the other party becomes  insolvent,  is adjudged a bankrupt
                  or  becomes  the  subject  of   dissolution,   liquidation  or
                  bankruptcy proceedings,  whether voluntarily or involuntarily.
                  or applies for  judicial  or  extra-judicial  settlement  with
                  creditors,  makes an assignment  for the benefit of creditors,
                  or otherwise discontinues business; or

<PAGE>

            (b)   If  the  other  party  is in  breach  of  any  of  the  terms,
                  conditions  or  representations  of  this  Agreement  and  the
                  breaching  party  shall  fall to  remedy  such  breach  to the
                  satisfaction  of the  breaching  party within thirty (30) days
                  from the date of  written  notice  by the party  claiming  the
                  breach.

      14.3  Termination  of this  Agreement  by either  party  shall be  without
            prejudice to any other rights or remedies that either party may have
            by virtue of any breach of the terms of this  Agreement In the event
            of termination of this Agreement for any reason,  MEDISCIENCE  shall
            promptly  account  for and pay  Royalties  accrued up to the date of
            such  termination,  Within ten (10) days after  termination  of this
            Agreement,  MEDISCIENCE  shall  cease  and  desist  all  use  of the
            Foundation "Attachment A" Technology and shall either (a) return ail
            Licensed  Products in MEDISCIENCE 's possession or under its control
            or (b) provide evidence of the disposal of si such products.

                                   ARTICLE 15
                                   USE OF NAME

      15.1  MEDISCIENCE  shall  not use the name or any logo,  seal.  Trademark,
            trade  name or  other  proprietary  mark  of  FOUNDATION,  The  City
            University of New York, or City College, nor any adaptation thereof,
            for advertising,  promotion or sales,  without prior written consent
            obtained from FOUNDATION in each case,  except that  MEDISCIENCE may
            state that it is  licensed  by  FOUNDATION  as is  provided  by this
            Agreement MEDISCIENCE shall not Issue any press release with respect
            to this Agreement  without the prior  approval of  FOUNDATION,  such
            approval  not to be  unreasonably  withheld  the terms of Article 15
            shall not apply to or in any way limit  required  SEC 8-K,  10-K and
            related   required   disclosures   of  Material   Event  filings  by
            MEDISCIENCE-

      15.2  Where  FOUNDATION or CUNY issue press  releases that refer to patent
            material   reflected  in  "Attachment   A*   MEDISCIENGE   shall  be
            "identified appropriately.

                                   ARTICLE 16
               UNITED STATES GOVERNMENT EXPORT CONTROL REGULATIONS

      16.1  FOUNDATION  warrants and represents  that it does not intend to, nor
            will,  directly or indirectly,  export or transmit the Technology or
            Licensed  Products,  in whole or in part,  or any related  technical
            information  or  materials,  to any  country in which such export or
            transmission  is restricted  by any  applicable  U.S.  regulation or
            statute,  without prior written approval, if required, of the Bureau
            of Export  Administration  of the U.S.  Department  of Commerce,  or
            other such  governmental  entity as may have  jurisdiction over such
            export or transmission.

                                   ARTICLE 17
                            MISCELLANEOUS PROVISIONS

      17.1  Governing  Law.  This  Agreement   shall  be  construed,   governed,
            --------------
            interpreted and applied in accordance with the laws of (fie State of
            New York,  except that  questions  affecting  the  construction  and
            effect of any patent shall be  determined  by the law of the country
            in which the patent was granted,

<PAGE>

      17.2  Entire  Agreement. This Agreement constitutes  the entire  agreement
            -----------------
            between tie parties and where  conflicting,  supercedes  any and alt
            prior   agreements   relative  to  the  premises   contained  herein
            concerning  the  subject  matter  hereof  and  cannot be  changed or
            terminated   orally.  No  modification  or  waiver  of  any  of  the
            provisions hereof shall be effective unless in writing and signed by
            the parties hereto. There are no representations or warranties other
            than as expressly stated herein.

      17.3  No Waiver. The failure of either party hereto at any time to require
            ---------
            performance  by the other party of any  provision of this  Agreement
            shall not affect the right of such party to require  performance  of
            that  provision.  Any  waiver by either  party of any  breach of any
            provision  of this  Agreement  shall not  constitute a waiver of any
            continuing or succeeding  breach of such provision,  a waiver of the
            provision itself, or a waiver of any right under this Agreement

      17.4  Arbitration.  All  disputes  arising  out  of  or  related  to  this
            -----------
            Agreement that cannot be settled  amicably shall be settled by final
            and binding arbitration under the Commercial  Arbitration Rules (the
            "Rules")  of the  American  Arbitration  Association  by  three  (3}
            qualified  arbitrators  one of which shall come from the  investment
            banking  community,  unless the  parties  otherwise  agree to have a
            single arbitrator, appointed in accordance with the Rules. The place
            of such arbitration shall be New York, New York, and the arbitrators
            shall  apply  Federal  and the law of the  State  of New  York.  The
            arbitration  proceedings,  results and any award shall be maintained
            by the parties as confidential,

      17.5  Severability. The provisions of this Agreement are severable, and in
            ------------
            the event that any provisions of this Agreement are determined to be
            Invalid or  unenforceable  under any  controlling  body of law, such
            invalidity  or  unenforceability  shall  not in any way  affect  the
            validity or enforcability of the remaining provisions hereof.

      17.6  No Partnership. This Agreement 'does not constitute and shall not be
            --------------
            construed as  constituting  a partnership  or joint venture  between
            MSDISCIENCE  and  FOUNDATION,  Neither party shall have any right to
            obligate or bind the other party in any manner whatsoever.

      17.7  Payment Notice. Any payment,  notice or other communication pursuant
            --------------
            to this license shall be  sufficiently  made or given on the date of
            mailing  if sent to  such  party  by  U.S.  mail,  postage  prepaid,
            Certified or registered,  return receipt requested,  or by overnight
            courier,  addressed  to it  at  its  address  below  or as it  shall
            designate by written notice given to the other party;

            To FOUNDATION:
            Mr. Frederick Chin
            Director of Grants & Contracts
            The Research Foundation of CUNY
            555 West 57th Street
            New York, N,Y. 10019

<PAGE>

            To  MEDISCIENCE:

            Peter Katevatis Esq.
            Chairman
            Mediscience Technology Corporation
            1235 Folkstone Way
            Cherry Hill, NJ 08034

      IN WITNESS  WHEREOF,  the parties hereto have hereunto set their hands and
seals and duly executed this Agreement the date first above written.

THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
BY: /s/ Edward Kile
    ---------------
    Edward Kile
TITLE: Chairman

MEDSCIENCE
BY:/s/ Peter Katevatis, June 10, 2002
   ----------------------------------
   Peter Katevatis

<PAGE>

                                  ATTACHMENT A

Medical Diagnostic Optical technology

      1.    #5,042,494,  August 27, 1991,  Method and  Apparatus  for  Detecting
            Cancerous  Tissue  using  Luminescence  Excitation  Spectra,  R.  R.
            Alfano.

      2.    #5,131,398,  July 21, 1992, Method and Apparatus for  Distinguishing
            Cancerous  Tissue from Benign Tumor Tissue,  Benign Tissue or Normal
            Tissue using Native Fluorescence, R. R. Alfano, B. Das, G. Tang.

      3.    #5,261,410, November 16, 1993, Method for determining if a Tissue is
            a Malignant Tumor Tissue, a Benign Tumor Tissue,  or a Normal Benign
            Tissue  using Raman  Spectroscopy,  R. R. Alfano,  C.-H.  Liu, W. S.
            Glassman.

      4.    #5,293,872,  March  15,  1994,  Method  for  Distinguishing  between
            Calcified  Atherosclerotic Tissue and Fibrous Atherosclerotic Tissue
            or Normal  Cardiovascular  Tissue  Using Raman  Spectroscopy,  R. R.
            Alfano, C. H. Liu

      5.    #5,348,018,  September 20, 1994, Method for determining if Tissue is
            Malignant   as  opposed   to   Non-Malignant   using   Time-Resolved
            Fluorescence Spectroscopy,  R. R. Alfano, A. Pradhan, G. C. Tang, L.
            Wang, Y. Budansky, B. B. Das.

      6.    #5,413,108,  May 9, 1995,  Method and Apparatus for Mapping a Tissue
            Sample for and  Distinguishing  Different  Regions  thereof based on
            Luminescence Measurements of Cancer-indicative Native Fluorophor, R.
            R. Alfano.

      7.    #5,467,767,  November 21, 1995,  Method for Determining if Tissue is
            Malignant   as  opposed   to   Non-Malignant   using   Time-resolved
            Fluorescence Spectroscopy,  R. R. Alfano, Asima Pradhan, G. C. Tang,
            L. Wang, Y. Budansky, B. B. Das.

      8.    #5,635,402,  June 3, 1997.  Technique for Determining whether a Cell
            is   Malignant   as  opposed  to   Non-malignant   using   Extrinsic
            Fluorescence  Spectroscopy,  R. R. Alfano, Cheng H. Liu, Wei L. Sha,
            Yury Budansky.

      9.    #5,769,081,  June 23, 1998,  Method for Detecting  Cancerous  Tissue
            using Optical  Spectroscopy and Fourier  Analysis,  R. R. Alfano, A.
            Katz, Y. Yang.

      10.   #5,849,595,  December 15, 1998, Method for Monitoring the Effects of
            Chemotherapeutic  Agents on Neoplasmic  Media,  R. R. Alfano,  G. C.
            Tang, S. P. Schantz.

      11.   #5,983,125,  November  9,  1999,  Method and  apparatus  for in vivo
            examination of subcutaneous  tissues inside an organ of a body using
            optical spectroscopy, R. R. Alfano, Y. Budansky.

      12.   #6,006,001,  December  21,  1999,  Fiber  optic  assembly  useful in
            optical spectroscopy, R. R. Alfano, S. Demos, G. Zhang.

      13.   #6,080,584,  June 27, 2000,  Method and  apparatus for detecting the
            presence of cancerous and precancerous cells in a smear using native
            fluorescence  spectroscopy,  Robert R. Alfano,  Singaravelu Ganesan,
            and Yury Budansky.

      14.   #6,091,985,  July 18,  2000,  Detection  of cancer and  precancerous
            conditions  in  tissues  and/or  cells  using  native   fluorescence
            excitation  spectroscopy,  Robert R.  Alfano,  Singaravelu  Ganesan,
            Alvin Katz, Yang Yuanlong.

<PAGE>

Optical Imaging for Medical Purposes

      1.    #5,371,368,  December 6, 1994,  Ultrafast Optical Imaging of Objects
            in a Scattering Medium, R. R. Alfano, P. P. Ho, L. Wang.

      2.    #5,625,458, April 29, 1997, Method and System for Imaging Objects in
            Turbid Media using  Diffusive  Fermat Photons,  R. R. Alfano,  A. Y.
            Polishchuk.

      3.    #5,644,429, July 1, 1997 (see #5,371,368),  2-Dimensional Imaging of
            Translucent  Objects in Turbid  Media,  R. R.  Alfano,  P. P. Ho, X.
            Liang.

      4.    #5,710,429,  January 20, 1998,  Ultrafast Optical Imaging of objects
            in or Behind Scattering Media, R. R. Alfano, Feng Liu, Q. Z. Wang P.
            Ho, L. M. Wang, X. Liang.

      5.    #5,719,399,  February  17,  1998,  Imaging and  Characterization  of
            Tissue based upon the  Preservation of Polarized  Light  transmitted
            therethrough, R. R. Alfano, S. G. Demos.

      6.    #5,799,656,  September 1, 1998, Optical Imaging of Breast Tissues to
            enable the Detection therein of Calcification  Regions Suggestive of
            Cancer, R. R. Alfano, P. P. Ho, L. Wang, X. Liang, P. Galland.

      7.    #5,813,988,  September 29, 1998, Time Resolved Diffusion Tomographic
            Imaging in Highly  Scattering Turbid Media, R. R. Alfano, W. Cai, F.
            Liu, M. Lax, Bidyut B. Das.

      8.    #5,847,394,  December  8, 1998,  Imaging  of Objects  Based upon the
            Polarization or Depolarization of Light, R. R. Alfano, S. G. Demos.

      9.    #5,931,789,  August 3, 1999,  Time-resolved diffusion tomographic 2D
            and 3D imaging in highly scattering turbid media,  Robert R. Alfano,
            Wei Cai, Feng Liu, Melvin Lax.

      10.   # 6,208,886  B1, March 27, 2001,  Non-linear  optical  tomography of
            turbid media, Robert R. Alfano, Yici Guo, Feng Liu, Ping Pei Ho.

      11.   #  6,215,587,  April 10,  2001,  Microscope  imaging  inside  highly
            scattering media, Robert R. Alfano, Gordon Anderson, Feng Liu.Exhibit 10.3

                                    AGREEMENT
                                    ---------

THIS AGREEMENT (the "Agreement") is EFFECTIVE as of the 1st day of August,  2004
by and between consultant John Matheu ("JM" or "Consultant"), with his principal
address at 215 Long Hill Drive,  Short Hills,  New Jersey 07078 and  Mediscience
Technology  Corp.  ("MDSC"  or  "Company")  with its  principal  address at 1235
Folkstone Way, Cherry Hill, New Jersey 08034. (Collectively the "Parties")

                                   WITNESSETH:

WHEREAS,  JM provides a wide  spectrum of  management  consulting  and ancillary
services  on  behalf  of  MDSC  in the  biopharmaceutical,  medical  devise  and
healthcare  industry  with  particular  expertise in  corporate,  financial  and
PRESENT project management at CUNY; and;

WHEREAS,  MDSC is a medical  device R&D company  with an  expressed  interest in
retaining the services of JM.

NOW,  THEREFORE,  in consideration  of the foregoing  premises and the terms and
conditions  set  forth  below,  the  adequacy  of which is  acknowledged  by the
parties, the parties hereby agree as follows:

DEFINITIONS AS USED HEREIN:

"Extension" shall mean that period following the end of the initial Term.

"Products"  shall mean those products that are owned by or in any way embody the
Technology or Intellectual Property Rights of MDSC

"Services"   shall   mean   those   services   JM  shall   perform   under   the
direction/supervision   of  Michael  Engelhart   President  COO  of  Mediscience
Technology hereunder during the Term. relating to the successful  accomplishment
of the following: Exhibit A

                                    Exhibit A
                                    ---------
               MEDICAL PROJECT MANAGEMENT GUIDE FOR CD-RATIOMETER
               --------------------------------------------------

1.    May Initiate and Evaluate Design of CD GYN Ratiometer
o     Review CD ratiometer layout and optical-mechanical drawings.
o     Determine physician requirements for GYN data collection.
o     Finalize  selection of optical  probe for use in cervical  cancer  testing
      device
o     Determine  electronic  control  board and  interface  for  physician  work
      station.
o     Design a study protocol for cervical cancer detection

2.    June  Final  Designs  and FDA  Approach  o Work with  management  in o FDA
      approach
o     Clinical development planning o Attend pre-IDE meeting
o     Identify and qualify potential study sites for clinical trials o Interface
      with front end software interface team.
o     Work with design  trifurcated  optical fiber probe, and disposable ferrule
      for fiber probe.
o     Develop calibration standards and test procedures for CD Ratiometer

                                       1

<PAGE>

3.    July Operational Manual, IDE and Approach for CD GYN Ratiometer
o     Continued work in developing user-friendly software.
o     Work with management to create the operational manual
o     Work with management to create approach to physicians - adoption equation
o     Work with management in preparing IDE
o     Attend FDA IDE meeting
o     Secure IRB's for

4.    Aug. - Sept. - Oct. Test prototype CD GYN Ratiometer for Clinical  Testing
      and 510 (k) Development and Submission
o     Test operation of prototype unit.
o     Test operation of physician interface.
o     Test CD-Ratiometer on ex vivo tissue specimens.
o     Train Mediphotonics and medical personnel.
o     Complete operational guide
o     Quality control clinical sites

"Technology" shall mean all present and future patented,  proprietary technology
and  intellectual  know-how,  and shop  knowledge  relating to products  for the
screening,  diagnosis,  and  treatment  of  patients  with  tumor  types  (e.g.,
including,  but  not  limited  to  colon,  lung,  cervix,  pancreas,   prostate,
esophageal, oral and breast).

"Term" shall mean an initial  minimum  period of 13 Months and the  extension of
the minimum period as described under the section "The Term" below commencing on
the date hereof.

"Territory" shall mean CUNY, RELATED LOCATIONS AND the world.

1 Services. JM shall provide such strategic,  management, and financial services
to MDSC as may be mutually agreed, which can include advising and assisting MDSC
in developing  budgets,  business and operating  plans,  staffing  requirements,
clinical protocols, relationships with clinical test sites and contract research
organization,   regulatory  process,  analysis  of  competing  technologies  and
potential technology,  acquisitions,  marketing strategies, strategic alliances,
including the  negotiation  process,  with  potential  Licensees,  Assignees and
Transferees and other strategic transactions; present MDSC's technology/products
to venture groups, individual investors,  investment bankers, VCs and others, as
required.  Unless  mutually  agreed  to  otherwise,  JM  will  be  dedicated  to
fulfilling these responsibilities on a full-time basis

2 The Term:  The initial  Term to be effective on August 1, 2004 and conclude on
September 31, 2005 unless otherwise extended by Board of Director approval. upon
review of JM performance hereunder. and recommendation by COO Michael Engelhart.

3 Compensation.  In full and complete  consideration of the Services by JM, MDSC
agrees  to pay JM a  monthly  fee  (executed  on the 15th day of each  month) of
$4,166 effective August 1, 2004 subject to a good faith re-appraisal upon
1.    a successful next round financing and
2.    the accomplishment of the CUNY project EXHIBIT A
Additionally,  MDSC herein  grants JM a n option,  effective  August1,  2004, to
purchase three hundred thousand (300,000) shares of MDSC restricted per SEC rule
14 common stock at one dollar fifty cents($.1.50) per share.

                                       2

<PAGE>

      4.    Expenses.  MDSC shall  reimburse  JM,  when  billed,  for any out-of
            pocket  expenses that JM might incur in the  performance of services
            hereunder.

      5.    Indemnification.  MDSC agrees to indemnify and hold harmless JM from
            and against any claims, liabilities, judgements, penalties and costs
            incurred as a party to any litigation or other proceeding, which may
            arise relating to or as a result of this Agreement.

      5     Independent  Contractor.  Each party is an independent contractor of
            the other and shall not be deemed to be an employee,  partner, agent
            or joint venturer of the other for any purpose.

4 Taxes: It is understood that payments to for services rendered will be made in
-------
full  at the  rate  agreed,  without  any  deductions  for  taxes  of  any  kind
whatsoever,  this  being in  conformity  with your  non-employee  status.  It is
understood  that any taxes that may be due and  payable as a result of  payments
herein  specified  by MDSC to you will be entirely  your  responsibility.  It is
understood  that, as part of this  Agreement,  you undertake to pay all taxes to
which you may be liable on such payments when due.

5 Patent Rights/ Intellectual  property:  You will promptly disclose to MDSC any
---------------------------------------
invention  arising  from  your  work  under  this  agreement.  MDSC  will be the
exclusive  owner of any such  invention and you will execute such  documents and
take  such  appropriate  action  (at  MDC's  expense)  as  may be  necessary  or
appropriate to establish  such ownership and to Assist MDC in obtaining  patents
thereon in the United States and/or foreign countries

6  Publication:  You must  obtain  MDSC's  prior  approval  for any  publication
--------------
relating to your work under this Agreement,  or to information  disclosed to you
by MDSC in connection  with this  Agreement,  both as to the content and time of
publication.

7  Confidentiality:  You  will  not  use,  other  than  in the  course  of  your
------------------
consultatntship  or disclose to third parties,  any confidential  information of
MDSC  which is  furnished  or  acquired  by you in the course of work under this
Agreement. All reports,  documents and any other materials or data loaned to you
for  purposes of  performing  your work are the  property  of MDSC,  and must be
retuned at the  earlier  of the  expiration  of this  Agreement  or upon  MDSC's
request.

8  Modification:  No term or  provision  of this  Agreement  may be  changed  or
---------------
modified except in writing signed by both parties. Oral changes or modifications
will not be binding,

10  Termination.  The parties  agree that this  Agreement  may be  terminated by
Mediscience  Technology at its sole discretion subject to 30 days written notice
to JM to his principal  address at 215 Long Hill Drive,  Short Hills, New Jersey
07078

11 Miscellaneous.

      1     This  Agreement  shall be governed and construed in accordance  with
            the laws of the State of New York and the  parties  hereto  agree to
            submit any  dispute  whatsoever  to the New York City  office of the
            American  Arbitration  association  for  full,  final  and  bind9ing
            resolution any dispute hereunder.

                                       3

<PAGE>

      2     This Agreement may be executed in counterparts,  each of which shall
            be deemed an original, but all of which shall constitute one and the
            same instrument

      3.    This Agreement constitutes the entire agreement between the parties,
            and supersedes all prior oral and written  proposals or agreements .

      4     Any  provision  of  this  Agreement  which  is  held  to be  void or
            unenforceable  shall be deemed  severable  from the remainder of the
            Agreement and shall not affect,  in any manner,  the validity or the
            enforceability of the other provisions hereof

      5     This  Agreement  can not be assigned by a party  without the written
            consent of the other party.

      6.    A failure of either party to assert any rights under this  Agreement
            shall not constitute a waiver of such rights, at that time or in the
            future.

      7.    This Agreement may be amended,  supplemented,  or modified only by a
            writing signed by both parties

      8.    The  individuals  signing  on behalf of their  respective  companies
            represent that they are duly authorized to do so.

IN WITNESS  WHEREOF,  the parties have  executed  this  Agreement as of the date
first written above.
This agreement is entered into pursuant to Board of Director  authority  wherein
John Matheu recused as a present member

Mediscience Technology Corp.                     John Matheu

By:  /s/ Peter Katevatis                         By: /s/John Matheu
     ----------------------------                    --------------
     Peter Katevatis Chairman/CEO                      John Matheu

Date:                                            Date:
      ---------------------------                     --------------------------

                                       4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}]]